This includes General Dynamics (GD), Lockheed Martin (LMT), and RTX (RTX). In the drug sector, Bristol-Myers (BMY), Merck (MRK), Pfizer (PFE), GSK (GSK), and AbbVie (ABBV) are worth considering. ETFs ...

New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.

The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023. Last ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

An initiative to improve care and standardize identification, assessment, referrals, and treatment for patients with HCM has been launched by the AHA.

Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

Maplewood 55, Chalker 30 — The Rockets toppled the Wildcats to break a two-game skid. Ethan Nevinski led the offensive charge, totaling 18 points Tuesday night and Kenyan Clover lent 12 points in the ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...